

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The ongoing Phase II SWOG-S1505 trial is evaluating perioperative \_\_\_\_\_ for patients with resectable adenocarcinoma of the pancreas.
  - a. FOLFOXIRI
  - b. Modified FOLFIRINOX
  - c. Gemcitabine/*nab* paclitaxel
  - d. All of the above
  - e. Both a and b
  - f. Both a and c
  - g. Both b and c
2. Nal-IRI is FDA approved \_\_\_\_\_ for patients with metastatic pancreatic cancer who have already received a gemcitabine-based regimen.
  - a. As monotherapy
  - b. In combination with 5-FU/LV
3. Which of the following categories reflects the mechanism of action of veliparib?
  - a. Antibody-drug conjugate
  - b. Anti-PD-1/PD-L1 antibody
  - c. Cancer stemness inhibitor
  - d. PARP inhibitor
4. The ongoing Phase II SWOG-S1513 trial is evaluating FOLFIRI alone versus modified FOLFIRI with veliparib as \_\_\_\_\_ for metastatic pancreatic cancer.
  - a. First-line therapy
  - b. Second-line therapy
  - c. Late-line therapy
5. BRCA mutations occur in approximately \_\_\_\_\_ of patients with pancreatic cancer.
  - a. 0%
  - b. 1% to 10%
  - c. 11% to 20%
  - d. 21% to 30%
6. Which of the following categories reflects the drug class of the agent PEGPH20?
  - a. Anti-PD-1/PD-L1 antibody
  - b. MEK inhibitor
  - c. Recombinant human hyaluronidase enzyme
7. During Phase II studies with PEGPH20, some patients experienced \_\_\_\_\_ requiring prophylaxis.
  - a. Fatigue
  - b. Nausea
  - c. Venous thromboembolic events
  - d. All of the above
8. PEGPH20 in combination with \_\_\_\_\_ has demonstrated encouraging activity in patients with metastatic pancreatic ductal adenocarcinoma.
  - a. FOLFIRINOX
  - b. Gemcitabine/*nab* paclitaxel
  - c. Both a and b
  - d. Neither a nor b
9. An exploratory analysis of the Phase III MPACT trial, which evaluated gemcitabine alone or in combination with *nab* paclitaxel as first-line therapy for metastatic pancreatic cancer, demonstrated significant tumor shrinkage benefit with the combination for both primary pancreatic and metastatic lesions.
  - a. True
  - b. False
10. A meta-analysis published by Sonbol and colleagues suggested the combination of 5-FU and irinotecan-containing regimens to be \_\_\_\_\_ to 5-FU and oxaliplatin as second-line therapy for pancreatic ductal adenocarcinoma.
  - a. Equivalent
  - b. Inferior
  - c. Superior